Previous 10 | Next 10 |
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. The $1.4 billion landmark deal between Beijing's BeiGene and Celgene (now Bristol-Myers) is falling apart. The companies are arguing over BeiGene's C...
SHANGHAI and SAN FRANCISCO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual inv...
LianBio, a Princeton, NJ-Shanghai biopharma, has filed for a $100 million IPO on the NASDAQ exchange. According to a Bloomberg article, I-Mab is in wide-ranging discussions with US and EU biopharmas for a deal that could out-license an I-Mab asset or involve a direct investment in the...
-- Demonstrated efficacy and safety consistent with global SOPHIA study -- Company expects to file BLA in China in advanced HER2+ breast cancer by approximately year end 2021 SHANGHAI and SAN FRANCISCO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an i...
SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) partner Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced t...
Final data collection is expected in the first half of 2022 SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology com...
Halvorsen's 13F portfolio value decreased marginally from $33.58B to $32.98B this quarter. The number of positions decreased from 94 to 88. Viking Global added FIGS Inc. & JD.com and increased Amazon.com & General Electric during the quarter. The top three positions are Am...
-- Expects to have more than 15 marketed products in more than 35 indications by 2025 -- Aspires to become a leading global biopharmaceutical company SHANGHAI and SAN FRANCISCO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-sta...
Schrodinger's software platform has transformed the way therapeutics are discovered. The platform is licensed to pharmaceuticals, biotechs, materials companies, universities, and government labs worldwide. In addition, currently at preclinical stage, the company is working on thre...
Shares of Entasis Therapeutics (ETTX +14.6%) are up sharply after the journal Nature published an article on the potential of its preclinical candidate ETX0462, which could become the first of a new class of antibiotics. ETX0462 is under development for multidrug-resistant Gram-negative and b...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...